This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
breast milk | 561 |
human milk | 339 |
preterm infants | 330 |
intensive care | 318 |
birth weight | 280 |
necrotizing enterocolitis | 235 |
care unit | 206 |
mechanical ventilation | 177 |
risk factors | 174 |
respiratory tract | 171 |
premature infants | 168 |
respiratory syncytial | 159 |
low birth | 157 |
syncytial virus | 152 |
neonatal intensive | 146 |
term infants | 142 |
mg kg | 141 |
gestational age | 141 |
weight infants | 134 |
somatic dysfunction | 116 |
fi rst | 114 |
neonatal sepsis | 107 |
respiratory distress | 105 |
united states | 103 |
escherichia coli | 99 |
lower respiratory | 98 |
breastfed infants | 90 |
infants born | 90 |
young children | 86 |
immune system | 85 |
respiratory failure | 84 |
septic shock | 82 |
increased risk | 80 |
virus infection | 78 |
fi bers | 74 |
hand hygiene | 74 |
fed infants | 72 |
preterm neonates | 67 |
may also | 65 |
signifi cant | 65 |
expressed breast | 64 |
exclusive breastfeeding | 63 |
newborn infants | 63 |
risk factor | 63 |
onset sepsis | 63 |
late preterm | 63 |
controlled trial | 62 |
infection control | 61 |
acute respiratory | 59 |
critically ill | 58 |
immune response | 58 |
infectious diseases | 57 |
pregnant women | 57 |
upper respiratory | 57 |
nitric oxide | 56 |
hospital stay | 56 |
mortality rate | 56 |
respiratory infections | 55 |
tract infections | 55 |
otitis media | 55 |
health care | 55 |
nosocomial infection | 54 |
cranial base | 54 |
prospective study | 54 |
infants younger | 52 |
heart disease | 52 |
oral feeding | 52 |
distress syndrome | 52 |
two groups | 52 |
rotavirus infection | 52 |
febrile infants | 51 |
high risk | 51 |
pediatric patients | 51 |
ml kg | 51 |
nervous system | 51 |
staphylococcus aureus | 51 |
gastrointestinal tract | 50 |
lung function | 49 |
kg day | 49 |
temporal bones | 49 |
cohort study | 49 |
temporal bone | 49 |
congenital heart | 49 |
west nile | 49 |
doc id | 48 |
cord uid | 48 |
vertical transmission | 48 |
viral bronchiolitis | 48 |
antimicrobial therapy | 48 |
infl uenza | 48 |
identifi ed | 48 |
respiratory illness | 47 |
respiratory viruses | 46 |
tract infection | 46 |
blood flow | 46 |
inflammatory response | 45 |
significantly higher | 45 |
fl exion | 45 |
healthy infants | 45 |
epithelial cells | 45 |
virus type | 45 |
frontal bone | 44 |
acute bronchiolitis | 44 |
viral infections | 44 |
nile virus | 44 |
among infants | 43 |
older children | 43 |
lung disease | 43 |
upper thoracic | 43 |
gut microbiota | 43 |
airway pressure | 43 |
viral infection | 42 |
via breast | 42 |
pulmonary hypertension | 42 |
young infants | 42 |
pediatric intensive | 42 |
extremely low | 42 |
campylobacter jejuni | 42 |
cord blood | 42 |
soft palate | 41 |
refl ex | 40 |
bronchopulmonary dysplasia | 40 |
hypertonic saline | 39 |
onset preeclampsia | 39 |
may result | 39 |
early onset | 39 |
hiv transmission | 39 |
first year | 38 |
breast feeding | 38 |
upper airway | 38 |
newborn infant | 37 |
nasal cavities | 37 |
intestinal microbiota | 37 |
cervical spine | 37 |
oral cavity | 36 |
significant differences | 36 |
hyoid bone | 36 |
bacterial infection | 36 |
immunodeficiency virus | 36 |
severe disease | 36 |
infl uence | 36 |
systematic review | 36 |
allergic rhinitis | 36 |
care units | 35 |
human immunodeficiency | 35 |
oxygen saturation | 35 |
virus infections | 35 |
enteral feeding | 35 |
neonatal period | 35 |
chronic lung | 34 |
bacterial infections | 34 |
central nervous | 34 |
mechanically ventilated | 34 |
indigenous infants | 34 |
full feeds | 34 |
middle ear | 33 |
mammary gland | 33 |
children younger | 33 |
organ failure | 33 |
significantly lower | 33 |
blood pressure | 33 |
statistically significant | 33 |
diarrheal disease | 33 |
may contribute | 33 |
child transmission | 33 |
primary infection | 32 |
direct contact | 32 |
exclusively breastfed | 32 |
innate immune | 32 |
protective effect | 32 |
fl uid | 32 |
yellow fever | 32 |
nosocomial infections | 32 |
mouth breathing | 32 |
brachial plexus | 32 |
necrosis factor | 32 |
infl ammation | 32 |
internal rotation | 32 |
preterm infant | 31 |
late onset | 31 |
paranasal sinuses | 31 |
enteral nutrition | 31 |
acute viral | 31 |
first months | 31 |
infant feeding | 30 |
viral respiratory | 30 |
cardiac output | 30 |
fl attening | 30 |
term neonates | 30 |
nasal cavity | 30 |
full enteral | 30 |
transmission via | 30 |
severe respiratory | 29 |
continuous feeding | 29 |
bloodstream infections | 29 |
emergency department | 29 |
diffi cult | 29 |
nasal obstruction | 29 |
infants may | 29 |
vlbw infants | 29 |
respiratory infection | 29 |
hospitalized infants | 29 |
resistant staphylococcus | 29 |
refl exes | 29 |
neonatal infections | 29 |
study group | 29 |
thoracic spine | 28 |
infected infants | 28 |
randomized controlled | 28 |
mean age | 28 |
gi tract | 28 |
breast cancer | 28 |
significant difference | 28 |
nutritional status | 28 |
blood culture | 27 |
may occur | 27 |
important role | 27 |
common cause | 27 |
parenteral nutrition | 27 |
one case | 27 |
antimicrobial agents | 27 |
infants receiving | 27 |
refl ux | 27 |
peripheral blood | 27 |
respiratory viral | 27 |
one study | 26 |
rsv infection | 26 |
childhood asthma | 26 |
factors associated | 26 |
innate immunity | 26 |
external rotation | 26 |
intestinal flora | 26 |
high frequency | 26 |
live births | 26 |
day care | 26 |
heart rate | 26 |
least one | 26 |
intestinal tract | 26 |
control group | 26 |
long term | 26 |
respiratory system | 26 |
herpes simplex | 26 |
higher risk | 26 |
polymerase chain | 25 |
early childhood | 25 |
indirect principles | 25 |
data suggest | 25 |
via breastfeeding | 25 |
see table | 25 |
severe sepsis | 25 |
human metapneumovirus | 25 |
logistic regression | 25 |
clinical practice | 25 |
chain reaction | 25 |
intestinal mucosa | 25 |
human colostrum | 25 |
standard precautions | 25 |
control study | 25 |
adverse effects | 24 |
blood cultures | 24 |
airway obstruction | 24 |
dendritic cells | 24 |
case report | 24 |
fl ow | 24 |
serious bacterial | 24 |
first hours | 24 |
respiratory support | 24 |
respiratory symptoms | 23 |
study design | 23 |
urinary tract | 23 |
term equivalent | 23 |
gas exchange | 23 |
activating factor | 23 |
myofascial structures | 23 |
cholera toxin | 23 |
campylobacter enteritis | 23 |
ill children | 23 |
mortality rates | 23 |
infectious agents | 23 |
contact precautions | 23 |
growth factor | 23 |
fi ssure | 23 |
one patient | 23 |
blood cell | 23 |
cardiac surgery | 23 |
positive airway | 23 |
equivalent age | 23 |
immune responses | 23 |
disease control | 22 |
studies suggest | 22 |
infant formula | 22 |
may lead | 22 |
weeks gestation | 22 |
cesarean delivery | 22 |
small intestine | 22 |
infl ammatory | 22 |
medical care | 22 |
often associated | 22 |
adaptive immune | 22 |
clinically significant | 22 |
simplex virus | 22 |
difficile colonization | 22 |
host defense | 22 |
first days | 22 |
pulmonary function | 22 |
mg dl | 22 |
cow milk | 22 |
continuous positive | 22 |
cases per | 22 |
amniotic fluid | 22 |
retrospective study | 22 |
immune function | 22 |
among children | 22 |
premature neonates | 22 |
supplemental oxygen | 22 |
year period | 22 |
hospital admission | 21 |
within days | 21 |
salmonella infection | 21 |
nasolacrimal duct | 21 |
lung injury | 21 |
years old | 21 |
typhoid fever | 21 |
clinical course | 21 |
several studies | 21 |
multiple organ | 21 |
white blood | 21 |
clinical manifestations | 21 |
recurrent wheezing | 21 |
fl oor | 21 |
ductus arteriosus | 21 |
incubation period | 21 |
physical examination | 21 |
osteopathic procedures | 21 |
clinical features | 21 |
early infancy | 21 |
high mortality | 21 |
infants admitted | 21 |
pulse oximetry | 21 |
necrotising enterocolitis | 21 |
clinical diagnosis | 21 |
first month | 20 |
intermittent feeding | 20 |
feeding performance | 20 |
arterial blood | 20 |
neonatal necrotizing | 20 |
patient care | 20 |
developing countries | 20 |
one year | 20 |
american academy | 20 |
negative bacteria | 20 |
antibiotic therapy | 20 |
und die | 20 |
fatty acids | 20 |
premature infant | 20 |
year old | 20 |
renal failure | 19 |
low risk | 19 |
vaginal delivery | 19 |
among preterm | 19 |
feeding intolerance | 19 |
respiratory rate | 19 |
respiratory morbidity | 19 |
stool cultures | 19 |
body fluids | 19 |
public health | 19 |
infection rates | 19 |
blood gas | 19 |
large numbers | 19 |
host response | 19 |
shiga toxin | 19 |
within hours | 19 |
endotracheal tube | 19 |
cmv infection | 19 |
enteral feeds | 19 |
randomized trial | 19 |
one side | 19 |
infants less | 19 |
endothelial cells | 19 |
vascular resistance | 19 |
nasal breathing | 19 |
blood samples | 19 |
cytomegalovirus infection | 19 |
metabolic acidosis | 19 |
hiv infection | 19 |
umbilical cord | 19 |
secretory iga | 19 |
positive mothers | 19 |
cytokine production | 18 |
bloodstream infection | 18 |
pertussis vaccine | 18 |
antibiotic treatment | 18 |
tumor necrosis | 18 |
prospective cohort | 18 |
acute otitis | 18 |
infectious disease | 18 |
lymphoid tissue | 18 |
congenital infection | 18 |
pseudomonas aeruginosa | 18 |
data collection | 18 |
zoster virus | 18 |
clinical trials | 18 |
disease severity | 18 |
rst months | 18 |
immune globulin | 18 |
maternal infection | 18 |
neonatal infection | 18 |
controlled trials | 18 |
side effects | 18 |
infant mortality | 18 |
median age | 18 |
quality improvement | 18 |
milk samples | 18 |
preterm birth | 18 |
infants received | 18 |
infection occurs | 18 |
nasal mucosa | 18 |
fever virus | 18 |
yersinia enterocolitica | 18 |
postnatal days | 18 |
kg dose | 18 |
fluorescent antibody | 18 |
dysfunction may | 18 |
enteroaggregative escherichia | 18 |
birthweight infants | 18 |
diffi culty | 17 |
type i | 17 |
outcome assessment | 17 |
pulmonary vascular | 17 |
severe acute | 17 |
respiratory syndrome | 17 |
central venous | 17 |
previously healthy | 17 |
neonatal eating | 17 |
cerebrospinal fluid | 17 |
birth cohort | 17 |
intermittent bolus | 17 |
pacifi er | 17 |
tissue culture | 17 |
several days | 17 |
closely related | 17 |
intrauterine growth | 17 |
extremely premature | 17 |
clinical trial | 17 |
bacterial colonization | 17 |
evidence indicates | 17 |
systemic inflammatory | 17 |
two years | 17 |
orbital fi | 17 |
infants whose | 17 |
neonatal unit | 17 |
pulmonary hemorrhage | 17 |
pao fio | 17 |
cesarean section | 17 |
third trimester | 17 |
early life | 17 |
oral administration | 16 |
hemorrhagic fever | 16 |
infants aged | 16 |
airway disease | 16 |
study period | 16 |
vibrio cholerae | 16 |
associated pneumonia | 16 |
respiratory disease | 16 |
hcv rna | 16 |
epec gastroenteritis | 16 |
acute diarrhea | 16 |
determine whether | 16 |
present study | 16 |
mucous membranes | 16 |
infants hospitalized | 16 |
lymph nodes | 16 |
reactive protein | 16 |
delivery room | 16 |
iu day | 16 |
rst years | 16 |
mucosal immune | 16 |
severe bronchiolitis | 16 |
bloody diarrhea | 16 |
superior orbital | 16 |
single dose | 16 |
confidence interval | 16 |
bottle feeding | 16 |
first week | 16 |
eating outcome | 16 |
postnatal growth | 16 |
fi brous | 16 |
facial bones | 16 |
neonatal care | 16 |
rotavirus infections | 16 |
may affect | 16 |
healthy children | 16 |
significantly different | 16 |
age group | 16 |
critical care | 16 |
acute lower | 16 |
like receptor | 16 |
primary outcome | 15 |
bolus feeding | 15 |
may present | 15 |
human infants | 15 |
weight neonates | 15 |
golden hour | 15 |
infant gut | 15 |
born infants | 15 |
nasal injury | 15 |
may play | 15 |
molecular techniques | 15 |
infection via | 15 |
less common | 15 |
evidence suggests | 15 |
acellular pertussis | 15 |
nutritive sucking | 15 |
control measures | 15 |
orbital cavity | 15 |
infantile diarrhea | 15 |
high incidence | 15 |
bacterial sepsis | 15 |
family history | 15 |
oblique muscle | 15 |
viral load | 15 |
clinical characteristics | 15 |
compressive forces | 15 |
relative risk | 15 |
blood gases | 15 |
weight gain | 15 |
prism score | 15 |
formula feeding | 15 |
jugular foramen | 15 |
one infant | 15 |
brain injury | 15 |
child health | 15 |
mouth breathers | 15 |
maternal milk | 15 |
oxygen delivery | 15 |
per day | 15 |
occipital fl | 15 |
clinical outcomes | 15 |
immunologic benefits | 15 |
infants without | 15 |
endotracheal intubation | 15 |
particular attention | 14 |
milk may | 14 |
advisory committee | 14 |
nasal congestion | 14 |
world health | 14 |
case reports | 14 |
extremely preterm | 14 |
renal function | 14 |
statistical analysis | 14 |
medication use | 14 |
mean duration | 14 |
significant correlation | 14 |
health organization | 14 |
neonatal diarrhea | 14 |
paediatric intensive | 14 |
prevent transmission | 14 |
odds ratio | 14 |
frontal bones | 14 |
abdominal distention | 14 |
inflammatory mediators | 14 |
cranial fl | 14 |
cell count | 14 |
children admitted | 14 |
research network | 14 |
mature milk | 14 |
response syndrome | 14 |
energy expenditure | 14 |
neonatal mortality | 14 |
recent studies | 14 |
fi ndings | 14 |
abdominal pain | 14 |
gut microbiome | 14 |
lyme disease | 14 |
feeding protocol | 14 |
otherwise healthy | 14 |
pharyngeal wall | 14 |
gastroesophageal refl | 14 |
corresponding author | 14 |
specifi cally | 14 |
microbial community | 14 |
airfl ow | 14 |
person transmission | 14 |
occipital bone | 14 |
special care | 14 |
soft tissue | 14 |
lateral wall | 14 |
overall mortality | 14 |
nicu setting | 14 |
infected mothers | 14 |
tidal volume | 14 |
mean airway | 14 |
enteric pathogens | 14 |
human rotavirus | 14 |
lower airway | 14 |
disseminated intravascular | 14 |
lacrimal bone | 14 |
clinical presentation | 14 |
preterm group | 14 |
first postnatal | 14 |
median duration | 14 |
transmission occurs | 14 |
underlying disease | 14 |
pertussis cases | 14 |
complete blood | 14 |
term outcomes | 14 |
thoracic cage | 14 |
may reduce | 14 |
body weight | 14 |
bei der | 13 |
inhaled nitric | 13 |
infl uences | 13 |
congenital malformations | 13 |
socioeconomic status | 13 |
stimulating factor | 13 |
infant death | 13 |
mean difference | 13 |
chest radiograph | 13 |
lung volume | 13 |
newborn nursery | 13 |
oxygen therapy | 13 |
intraventricular hemorrhage | 13 |
care nursery | 13 |
statistical significance | 13 |
tumour necrosis | 13 |
two patients | 13 |
clinical conditions | 13 |
sample size | 13 |
infected neonates | 13 |
atopic dermatitis | 13 |
first weeks | 13 |
infi ltrates | 13 |
superior oblique | 13 |
multicenter study | 13 |
mit der | 13 |
two infants | 13 |
infant may | 13 |
first years | 13 |
umbilical artery | 13 |
per minute | 13 |
diffi culties | 13 |
molecular methods | 13 |
shock syndrome | 13 |
poor outcome | 13 |
bone marrow | 13 |
clostridium difficile | 13 |
functional residual | 13 |
serum levels | 13 |
one report | 13 |
mast cells | 13 |
six months | 13 |
gastric residual | 13 |
routine use | 13 |
clinical symptoms | 13 |
children born | 13 |
may require | 13 |
patent ductus | 13 |
oxygen requirement | 13 |
pneumocystis jirovecii | 13 |
cavernous sinus | 13 |
phase ii | 13 |
may help | 13 |
intravascular coagulation | 13 |
fl uids | 13 |
adverse events | 13 |
infant transmission | 13 |
milk allergy | 13 |
human breast | 13 |
ph group | 13 |
residual capacity | 13 |
cell leukemia | 13 |
binding protein | 13 |
informed consent | 13 |
neonatal rotavirus | 13 |
adult patients | 13 |
platelet activating | 13 |
higher incidence | 13 |
pediatric icu | 13 |
dengue virus | 13 |
supine position | 13 |
antimicrobial resistance | 13 |
blood count | 13 |
differential diagnosis | 13 |
regain birth | 13 |
salmonella gastroenteritis | 13 |
weeks pma | 13 |
wide range | 13 |
rsv bronchiolitis | 13 |
nosocomial transmission | 13 |
commercially available | 13 |
idiopathic scoliosis | 13 |
frequently associated | 13 |
randomized clinical | 12 |
plexus injury | 12 |
treatment group | 12 |
ebv infection | 12 |
disease associated | 12 |
surface area | 12 |
pulmonary artery | 12 |
feeding may | 12 |
time period | 12 |
nasal swabs | 12 |
persistent pulmonary | 12 |
hospital discharge | 12 |
milk contains | 12 |
will also | 12 |
usually occurs | 12 |
respiratory secretions | 12 |
see chapter | 12 |
candida species | 12 |
care workers | 12 |
broad spectrum | 12 |
plasma cells | 12 |
developed countries | 12 |
infantile colic | 12 |
severe cases | 12 |
clinical studies | 12 |
tract disease | 12 |
paramount importance | 12 |
git microbiota | 12 |
birth canal | 12 |
total body | 12 |
neonatal research | 12 |
respiratory virus | 12 |
multivariate analysis | 12 |
somatovisceral refl | 12 |
apgar score | 12 |
infection among | 12 |
antiretroviral therapy | 12 |
passively acquired | 12 |
lymphoid cells | 12 |
children aged | 12 |
milk feeding | 12 |
nach der | 12 |
may develop | 12 |
age years | 12 |
require mechanical | 12 |
maternal antibody | 12 |
ventilator settings | 12 |
droplet precautions | 12 |
airborne precautions | 12 |
risk infants | 12 |
positive infants | 12 |
seropositive mothers | 12 |
nasal cannula | 12 |
full oral | 12 |
virus bronchiolitis | 12 |
lymphatic drainage | 12 |
continuous infusion | 12 |
positive women | 12 |
intraosseous dysfunction | 12 |
environmental factors | 12 |
term infant | 12 |
secondary bacterial | 12 |
infant vitamin | 12 |
infants developed | 12 |
novel coronavirus | 12 |
four infants | 12 |
ttv dna | 12 |
smooth muscle | 12 |
nursery outbreaks | 12 |
south africa | 12 |
two cases | 12 |
generation cephalosporins | 12 |
zu einer | 12 |
even though | 12 |
lymphotropic virus | 12 |
bordetella pertussis | 12 |
previous studies | 12 |
clinical signs | 12 |
orbicularis oris | 12 |
predictive value | 12 |
head circumference | 12 |
tested positive | 12 |
nasal bones | 12 |
infants hospitalised | 12 |
previously described | 12 |
sudden infant | 12 |
achieve full | 12 |
gene expression | 12 |
gbs disease | 12 |
also present | 12 |
exact test | 12 |
ill patients | 12 |
jejuni enteritis | 12 |
pulmonary disease | 12 |
resource utilization | 12 |
streptococcus pneumoniae | 12 |
invasive disease | 12 |
chronic diarrhea | 12 |
three patients | 12 |
current study | 12 |
lacrimal sac | 12 |
eff ect | 12 |
icu syndrome | 12 |
acquired mrsa | 12 |
acute phase | 11 |
young infant | 11 |
term newborns | 11 |
control infants | 11 |
potential risk | 11 |
oxygen consumption | 11 |
common cold | 11 |
formula fed | 11 |
blood cells | 11 |
confi rm | 11 |
cranial somatic | 11 |
hospital length | 11 |
infantile gastroenteritis | 11 |
inclusion criteria | 11 |
pathogenic bacteria | 11 |
final manuscript | 11 |
regression model | 11 |
respiratory mechanics | 11 |
per live | 11 |
apgar scores | 11 |
month period | 11 |
ventilatory support | 11 |
infants days | 11 |
high prevalence | 11 |
infection due | 11 |
close contact | 11 |
small number | 11 |
manipulative treatment | 11 |
epidemiologic studies | 11 |
duct obstruction | 11 |
fi nger | 11 |
cardiopulmonary bypass | 11 |
microbiota composition | 11 |
collaborative study | 11 |
nebulized hypertonic | 11 |
increased mortality | 11 |
trigeminal nerve | 11 |
university hospital | 11 |
will help | 11 |
membrane disease | 11 |
blood products | 11 |
may increase | 11 |
dosing levels | 11 |
probiotic bacteria | 11 |
facial expression | 11 |
low birthweight | 11 |
fio ratio | 11 |
host immune | 11 |
parainfluenza virus | 11 |
persistent diarrhea | 11 |
incidence rate | 11 |
illness severity | 11 |
nutritional support | 11 |
asymptomatic infection | 11 |
oxygenation index | 11 |
readily available | 11 |
major cause | 11 |
infants compared | 11 |
ventilated children | 11 |
large number | 11 |
pneumatosis intestinalis | 11 |
lactating women | 11 |
milk protein | 11 |
venous blood | 11 |
study included | 11 |
also associated | 11 |
clinical picture | 11 |
death syndrome | 11 |
prospective studies | 11 |
infants will | 11 |
milk transmission | 11 |
infectious agent | 11 |
osteopathic practitioner | 11 |
three infants | 11 |
nucleic acid | 11 |
signifi cantly | 11 |
first day | 11 |
respiratory pathogens | 11 |
antibiotic resistance | 11 |
tracheal aspirates | 11 |
atopic disease | 11 |
significant risk | 11 |
maternal antibodies | 11 |
bronchiolitis severity | 11 |
south america | 11 |
petrous portion | 11 |
clostridium diflicile | 11 |
st year | 11 |
using indirect | 11 |
tertiary care | 11 |
osteopathic treatment | 11 |
older infants | 11 |
significant morbidity | 11 |
salmonella infections | 11 |
four patients | 11 |
retrospective cohort | 11 |
parainfl uenza | 11 |
immune systems | 11 |
significant decrease | 11 |
respiratory outcomes | 11 |
upper cervical | 11 |
performed using | 11 |
mucosal injury | 11 |
class ii | 11 |
upper incisors | 11 |
mucosal barrier | 11 |
postnatal infection | 11 |
streptococcal disease | 11 |
primary care | 11 |
watery diarrhea | 11 |
blood sampling | 11 |
nursery outbreak | 11 |
soft tissues | 11 |
infected children | 11 |
molecular epidemiology | 11 |
tobacco smoke | 11 |
well documented | 11 |
coli strains | 11 |
month old | 11 |
full term | 11 |
observational study | 11 |
medical center | 11 |
neurodevelopmental outcome | 11 |
red blood | 10 |
ct scan | 10 |
fl exibility | 10 |
carotid artery | 10 |
rsv season | 10 |
parainfluenza viruses | 10 |
may demonstrate | 10 |
postnatal transmission | 10 |
newborn period | 10 |
significantly increased | 10 |
clinical evidence | 10 |
respiratory illnesses | 10 |
children hospitalized | 10 |
working group | 10 |
mean gestational | 10 |
maternal vitamin | 10 |
control practices | 10 |
mit einem | 10 |
infants infected | 10 |
remains unclear | 10 |
scoring systems | 10 |
care centers | 10 |
may include | 10 |
group i | 10 |
neonatal outcome | 10 |
postmenstrual age | 10 |
herpes virus | 10 |
inflammatory cytokines | 10 |
aap committee | 10 |
leukemia virus | 10 |
identifi cation | 10 |
study found | 10 |
fecal leukocytes | 10 |
metabolic alkalosis | 10 |
uninfected infants | 10 |
reactive oxygen | 10 |
disease caused | 10 |
longitudinal study | 10 |
campylobacter fetus | 10 |
commonly used | 10 |
lung volumes | 10 |
immunosorbent assay | 10 |
compared using | 10 |
greater risk | 10 |
stool specimens | 10 |
household contacts | 10 |
organ dysfunction | 10 |
age groups | 10 |
hard palate | 10 |
birth asphyxia | 10 |
ill infants | 10 |
procedures may | 10 |
jirovecii detection | 10 |
healthy term | 10 |
tract illness | 10 |
epec infection | 10 |
onset neonatal | 10 |
respiratory mucosa | 10 |
internal carotid | 10 |
conventional mechanical | 10 |
cell types | 10 |
listeria monocytogenes | 10 |
empiric therapy | 10 |
one third | 10 |
forced expiratory | 10 |
another study | 10 |
elbw infants | 10 |
anterior part | 10 |
craniocervical junction | 10 |
complement activation | 10 |
vibrio fetus | 10 |
campylobacter coli | 10 |
severe illness | 10 |
staphylococcus epidermidis | 10 |
total parenteral | 10 |
periventricular leukomalacia | 10 |
linear regression | 10 |
etiologic agents | 10 |
spinal cord | 10 |
intestinal perforation | 10 |
zygomatic bones | 10 |
th week | 10 |
mononuclear cells | 10 |
fever vaccine | 10 |
patients admitted | 10 |
body composition | 10 |
expiratory pressure | 10 |
pectoral girdle | 10 |
jejuni infection | 10 |
microbial ecology | 10 |
muscular torticollis | 10 |
coronavirus disease | 10 |
alveolar macrophages | 10 |
greatest risk | 10 |
mediated immunity | 10 |
diff erence | 10 |
prenatal infection | 10 |
phase i | 10 |
inferior oblique | 10 |
material und | 10 |
liver disease | 10 |
hyaline membrane | 10 |
clinical data | 10 |
continued breastfeeding | 10 |
every hours | 10 |
study infants | 10 |
hcv infection | 10 |
pediatric septic | 10 |
lateral rectus | 10 |
vlbw infant | 10 |
febrile episodes | 10 |
severity score | 10 |
nasal cpap | 10 |
six infants | 10 |
growth retardation | 10 |
mass spectrometry | 10 |
takes place | 10 |
negative bacilli | 10 |
surfactant replacement | 10 |
clinical significance | 10 |
maternal age | 10 |
infection may | 10 |
toxic shock | 10 |
flow rate | 10 |
clinical scores | 10 |
humoral immunity | 10 |
gestational ages | 10 |
dysfunction affecting | 10 |
infants treated | 10 |
donor human | 10 |
i infection | 10 |
practice guidelines | 10 |
acute renal | 10 |
proinflammatory cytokines | 10 |
nursing staff | 10 |
poor feeding | 10 |
bloody stools | 10 |
femoral head | 10 |
im rahmen | 10 |
generally accepted | 10 |
lumbar lordosis | 10 |
refl ects | 10 |
may explain | 10 |
three months | 10 |
human herpes | 9 |
nk cell | 9 |
synostotic plagiocephaly | 9 |
included infants | 9 |
intestinal bacterial | 9 |
interquartile range | 9 |
ng ml | 9 |
clinical findings | 9 |
life support | 9 |
barrier function | 9 |
nasopharyngeal tonsil | 9 |
clinical research | 9 |
inspiratory pressure | 9 |
premature babies | 9 |
negative staphylococci | 9 |
developed nec | 9 |
one hand | 9 |
developing brain | 9 |
th percentile | 9 |
bacterial toxins | 9 |
preterm compared | 9 |
epithelial cell | 9 |
adaptive immunity | 9 |
primary objective | 9 |
bacterial co | 9 |
feeding assessment | 9 |
linked immunosorbent | 9 |
determined using | 9 |
mg ml | 9 |
effi cient | 9 |
less severe | 9 |
orbicularis oculi | 9 |
vaccine virus | 9 |
microbial colonization | 9 |
der adaptationsphase | 9 |
weight mean | 9 |
icu admission | 9 |
lung tissue | 9 |
breastfeeding mother | 9 |
mucous membrane | 9 |
das kind | 9 |
type ii | 9 |
will often | 9 |
pseudomembranous colitis | 9 |
metatarsus adductus | 9 |
may decrease | 9 |
infants demonstrate | 9 |
child will | 9 |
early diagnosis | 9 |
tibial torsion | 9 |
nursing mothers | 9 |
data support | 9 |
sagittal plane | 9 |
carbon dioxide | 9 |
deep cervical | 9 |
younger children | 9 |
ocular dysfunction | 9 |
amino acid | 9 |
measured using | 9 |
less likely | 9 |
frequently encountered | 9 |
positive pressure | 9 |
person spread | 9 |
increased rates | 9 |
ethics committee | 9 |
venous catheters | 9 |
affected infants | 9 |
kg min | 9 |
gel electrophoresis | 9 |
opposite side | 9 |
human neonatal | 9 |
weight loss | 9 |
lower incidence | 9 |
cell wall | 9 |
patients died | 9 |
clinical response | 9 |
paediatric ward | 9 |
low concentrations | 9 |
outcome measures | 9 |
pneumocystis carinii | 9 |
based techniques | 9 |
airborne transmission | 9 |
human bocavirus | 9 |
infection associated | 9 |
vagus nerve | 9 |
optic nerve | 9 |
described elsewhere | 9 |
protracted diarrhea | 9 |
peak inspiratory | 9 |
greater wing | 9 |
months old | 9 |
first study | 9 |
grade fever | 9 |
congenital anomalies | 9 |
virulence factors | 9 |
pulmonary tuberculosis | 9 |
randomised controlled | 9 |
medial pterygoid | 9 |
whole cell | 9 |
defense mechanisms | 9 |
signifi cance | 9 |
medical conditions | 9 |
nasal secretions | 9 |
acquired antibodies | 9 |
rotavirus diarrhea | 9 |
children less | 9 |
broad range | 9 |
higher rates | 9 |
chart review | 9 |
thoracoabdominal diaphragm | 9 |
maternal illness | 9 |
symptomatic infection | 9 |
volunteer studies | 9 |
gastrointestinal symptoms | 9 |
supportive care | 9 |
sleep apnea | 9 |
lower airways | 9 |
greater wings | 9 |
oral route | 9 |
influenza virus | 9 |
styloid processes | 9 |
least months | 9 |
donor milk | 9 |
vital capacity | 9 |
oxygen supplementation | 9 |
normal range | 9 |
two different | 9 |
widely used | 9 |
maxillary sinuses | 9 |
expiratory flows | 9 |
large amounts | 9 |
adhesion molecules | 9 |
hearing loss | 9 |
nec among | 9 |
hospitalized patients | 9 |
effective treatment | 9 |
medication errors | 9 |
rotavirus vaccines | 9 |
fl attened | 9 |
common causes | 9 |
defi nition | 9 |
head posture | 9 |
bioactive factors | 9 |
right side | 9 |
cn iii | 9 |
will result | 9 |
factors influencing | 9 |
seven infants | 9 |
dysenteriae serotype | 9 |
patients receiving | 9 |
mortality among | 9 |
nasal respiration | 9 |
animal models | 9 |
tissue texture | 9 |
breastfeeding infant | 9 |
commonly encountered | 9 |
infection rate | 9 |
onset disease | 9 |
important cause | 9 |
central line | 9 |
postural changes | 9 |
cn ix | 9 |
second year | 9 |
confi rmed | 9 |
human neonates | 9 |
congenital anomaly | 8 |
acute kidney | 8 |
klebsiella pneumoniae | 8 |
higher levels | 8 |
among neonates | 8 |
bovine milk | 8 |
thoracic kyphosis | 8 |
attack rate | 8 |
sore throat | 8 |
tube feeding | 8 |
severity scoring | 8 |
hospitalized children | 8 |
antibody responses | 8 |
neonatal necrotising | 8 |
abdominal wall | 8 |
und methoden | 8 |
northern territory | 8 |
comfort scale | 8 |
statistical difference | 8 |
many cases | 8 |
known risk | 8 |
intestinal epithelial | 8 |
assisted ventilation | 8 |
contaminated food | 8 |
fat mass | 8 |
epidemiologic data | 8 |
hospital course | 8 |
level iii | 8 |
milk antibodies | 8 |
mucosal surface | 8 |
blood volume | 8 |
small children | 8 |
important risk | 8 |
viral culture | 8 |
natural killer | 8 |
suffi cient | 8 |
fl ora | 8 |
five cases | 8 |
respiratory parameters | 8 |
respiratory insufficiency | 8 |
serratia marcescens | 8 |
dental arches | 8 |
sepsis may | 8 |
infant respiratory | 8 |
general population | 8 |
study population | 8 |
microbial invasion | 8 |
binding lectin | 8 |
neonatal resuscitation | 8 |
cd cells | 8 |
high fever | 8 |
auf der | 8 |
whole blood | 8 |
mucosal surfaces | 8 |
antigen presentation | 8 |
hbv vaccine | 8 |
early feeding | 8 |
free survival | 8 |
membrane oxygenation | 8 |
neurodevelopmental outcomes | 8 |
remains neutral | 8 |
laboratory findings | 8 |
severe rsv | 8 |
antiinflammatory effects | 8 |
transmission rate | 8 |
zygomatic bone | 8 |
widespread use | 8 |
clinical outcome | 8 |
bei reifgeborenen | 8 |
emergency care | 8 |
posterior border | 8 |
health status | 8 |
chest radiographs | 8 |
authors declare | 8 |
respiratory diseases | 8 |
animal studies | 8 |
positive end | 8 |
breast pumps | 8 |
sympathetic fi | 8 |
breast lesions | 8 |
child may | 8 |
pulmonary infections | 8 |
prolonged rupture | 8 |
premature birth | 8 |
discharged home | 8 |
among newborns | 8 |
gastroenteritis due | 8 |
cn xi | 8 |
growth factors | 8 |
wide variety | 8 |
pulmonary blood | 8 |
medical records | 8 |
factors may | 8 |
care medicine | 8 |
nasal patency | 8 |
serum antibody | 8 |
well described | 8 |
severe infections | 8 |
revised feeding | 8 |
per year | 8 |
medical staff | 8 |
empirical antibiotic | 8 |
infl uenced | 8 |
lumbar spine | 8 |
allergic diseases | 8 |
patient population | 8 |
picu admission | 8 |
room air | 8 |
immunodefi ciencies | 8 |
congenital muscular | 8 |
increased expression | 8 |
healthy infant | 8 |
formula milk | 8 |
onset gbs | 8 |
analyzed using | 8 |
onset group | 8 |
intestinal microbial | 8 |
respiratory status | 8 |
cell function | 8 |
mucociliary clearance | 8 |
ribosomal rna | 8 |
fungal infections | 8 |
hospital admissions | 8 |
three days | 8 |
newborn nurseries | 8 |
surfactant administration | 8 |
resistant organisms | 8 |
arterial oxygen | 8 |
phase angle | 8 |
platelet count | 8 |
published maps | 8 |
lactate levels | 8 |
jurisdictional claims | 8 |
auf die | 8 |
cell surface | 8 |
positive blood | 8 |
mit dem | 8 |
effective therapy | 8 |
ml min | 8 |
pterygomandibular raphe | 8 |
cfu ml | 8 |
der geburt | 8 |
intraosseous dysfunctions | 8 |
corrected age | 8 |
may become | 8 |
pressure ventilation | 8 |
high tsh | 8 |
cells may | 8 |
diabetes mellitus | 8 |
pregnant woman | 8 |
ventilated patients | 8 |
infant via | 8 |
antimicrobial agent | 8 |
myocardial dysfunction | 8 |
first dose | 8 |
neonatal herpes | 8 |
cell pertussis | 8 |
nosocomial outbreak | 8 |
thumb sucking | 8 |
findings suggest | 8 |
organ system | 8 |
requiring mechanical | 8 |
early weaning | 8 |
infant bronchiolitis | 8 |
uremic syndrome | 8 |
effi cacy | 8 |
practices advisory | 8 |
red book | 8 |
common respiratory | 8 |
cerebral palsy | 8 |
skin lesions | 8 |
femoral anteversion | 8 |
antigen detection | 8 |
type diabetes | 8 |
kcal kg | 8 |
diarrheal illnesses | 8 |
hbv infection | 8 |
young febrile | 8 |
cardiac arrest | 8 |
three times | 8 |
clinical examination | 8 |
randomised trial | 8 |
immunodefi ciency | 8 |
candida albicans | 8 |
positive effect | 8 |
versus intermittent | 8 |
adenotonsillar hypertrophy | 8 |
exclusion criteria | 8 |
indigenous children | 8 |
orofacial functions | 8 |
national institute | 8 |
organ systems | 8 |
two studies | 8 |
term group | 8 |
plasminogen activator | 8 |
feeding group | 8 |
methods used | 8 |
guidelines recommend | 8 |
nasal airway | 8 |
patients showed | 8 |
dysfunctional mechanics | 8 |
palatine bone | 8 |
stool culture | 8 |
therapy may | 8 |
case series | 8 |
pertussis vaccines | 8 |
immune cells | 8 |
monoclonal antibody | 8 |
antibiotic use | 8 |
obstructive sleep | 8 |
lower levels | 8 |
treated infants | 8 |
springer nature | 8 |
term outcome | 8 |
assessed using | 8 |
maternally acquired | 8 |
inspired oxygen | 8 |
infants weeks | 8 |
mean birth | 8 |
least hours | 8 |
tympanic membrane | 8 |
occurs via | 8 |
cardiac disease | 8 |
subgroup analysis | 8 |
nasogastric tube | 8 |
less frequently | 8 |
intrauterine infection | 8 |
also may | 8 |
old enough | 8 |
institutional affiliations | 8 |
among patients | 8 |
molecular patterns | 8 |
regression analysis | 8 |
exchange transfusion | 8 |
heat shock | 8 |
infections among | 8 |
asthmatic children | 8 |
average age | 8 |
respiratory problems | 8 |
neonatal respiratory | 8 |
every year | 8 |
continuing breastfeeding | 8 |
burdjalov score | 8 |
airway resistance | 8 |
three groups | 8 |
strains may | 8 |
thoracic vertebrae | 8 |
rescue therapy | 8 |
bumetanide excretion | 8 |
intravenous fluids | 8 |
breastfed infant | 8 |
american college | 8 |
double blind | 8 |
pediatric infectious | 8 |
blood supply | 8 |
one lrti | 8 |
solid foods | 8 |
family asthma | 8 |
infant botulism | 8 |
nature remains | 8 |
continuous monitoring | 8 |
acquired pneumonia | 8 |
septal defect | 8 |
acute illness | 8 |
infant pairs | 8 |
descriptive statistics | 8 |
rotavirus vaccine | 8 |
bacterial pathogens | 7 |
bacterial contamination | 7 |
specific infectious | 7 |
contributing factor | 7 |
may represent | 7 |
virus transmission | 7 |
strong evidence | 7 |
contaminated water | 7 |
well established | 7 |
medical management | 7 |
deaths occurred | 7 |
care professionals | 7 |
risk group | 7 |
test results | 7 |
short term | 7 |
feeding methods | 7 |
wheezing episodes | 7 |
four months | 7 |
premature neonate | 7 |
last years | 7 |
conflicting results | 7 |
transmammary transmission | 7 |
suspected sepsis | 7 |
antibody titer | 7 |
intestinal infection | 7 |
either side | 7 |
invasive ventilation | 7 |
potential confounders | 7 |
developing world | 7 |
whose mothers | 7 |
nursery personnel | 7 |
sri ramachandra | 7 |
paneth cells | 7 |
new york | 7 |
tissue perfusion | 7 |
disease occurs | 7 |
chronic pulmonary | 7 |
ml cm | 7 |
allergic disease | 7 |
recent study | 7 |
different types | 7 |
enteric disease | 7 |
normal saline | 7 |
low gestational | 7 |
experimental model | 7 |
oral iga | 7 |
within minutes | 7 |
dietary nucleotides | 7 |
first three | 7 |
nasal continuous | 7 |
hospital unit | 7 |
nosocomial sepsis | 7 |
animal model | 7 |
benefi cial | 7 |
specific antibodies | 7 |
times higher | 7 |
anterior surface | 7 |
mm hg | 7 |
der schwangerschaft | 7 |
feeding difficulties | 7 |
smallpox vaccination | 7 |
diarrheal illness | 7 |
mycoplasma pneumoniae | 7 |
emergency room | 7 |
may follow | 7 |
heart failure | 7 |
iga antibodies | 7 |
potential pathogens | 7 |
surfactant therapy | 7 |
gastrointestinal bleeding | 7 |
prone position | 7 |
optic canal | 7 |
human development | 7 |
milk versus | 7 |
disease onset | 7 |
current evidence | 7 |
invasive procedures | 7 |
conventional ventilation | 7 |
mit einer | 7 |
vascular permeability | 7 |
secretory component | 7 |
associated lymphoid | 7 |
class iii | 7 |
nasopharyngeal swabs | 7 |
th edn | 7 |
extracellular matrix | 7 |
year prospective | 7 |
feeding tubes | 7 |
high level | 7 |
respiratory effort | 7 |
ossifi cation | 7 |
oropharyngeal isthmus | 7 |
levator palpebrae | 7 |
lamina propria | 7 |
cell adhesion | 7 |
pcr assay | 7 |
normal values | 7 |
will develop | 7 |
reaching full | 7 |
parapneumonic effusions | 7 |
lower part | 7 |
middle east | 7 |
controlled study | 7 |
lower lip | 7 |
may predispose | 7 |
significant increase | 7 |
like receptors | 7 |
recent years | 7 |
diarrhea caused | 7 |
blood fl | 7 |
also affect | 7 |
also found | 7 |
chest wall | 7 |
kidney injury | 7 |
fecal microbiota | 7 |
fecal specimens | 7 |
associated molecular | 7 |
two times | 7 |
annular ligament | 7 |
severe asthma | 7 |
immunologic components | 7 |
nosocomial pneumonia | 7 |
drug administration | 7 |
relatively low | 7 |
potentially pathogenic | 7 |
protective role | 7 |
infection severity | 7 |
plasma exchange | 7 |
dosing level | 7 |
preterm formula | 7 |
antenatal steroid | 7 |
may need | 7 |
polymorphonuclear leukocytes | 7 |
significant number | 7 |
feeding versus | 7 |
institutional review | 7 |
months postpartum | 7 |
successful oral | 7 |
i i | 7 |
mucus production | 7 |
raw milk | 7 |
i transmission | 7 |
connective tissues | 7 |
extracorporeal membrane | 7 |
breast fed | 7 |
successful treatment | 7 |
food allergy | 7 |
oscillatory ventilation | 7 |
days old | 7 |
fi brosis | 7 |
peak incidence | 7 |
maternal prenatal | 7 |
frequency oscillatory | 7 |
one week | 7 |
fl exed | 7 |
abdominal pressure | 7 |
fi ngers | 7 |
viral etiology | 7 |
chronic disease | 7 |
independent risk | 7 |
squamous portion | 7 |
chain fatty | 7 |
preschool children | 7 |
community acquired | 7 |
system involvement | 7 |
enterobacter cloacae | 7 |
bactericidal permeability | 7 |
maxillary sinus | 7 |
bis zum | 7 |
dynamic compliance | 7 |
data show | 7 |
higher proportion | 7 |
neutrophil extracellular | 7 |
breastfeeding mothers | 7 |
several weeks | 7 |
life may | 7 |
infants showed | 7 |
white matter | 7 |
surgical site | 7 |
one hundred | 7 |
innerhalb der | 7 |
bacterial pneumonia | 7 |
cranial extension | 7 |
infants receive | 7 |
inherent motility | 7 |
perinatal infection | 7 |
rsv disease | 7 |
pooled analysis | 7 |
cdc recommends | 7 |
infants followed | 7 |
campylobacter infection | 7 |
rst molar | 7 |
table shows | 7 |
expiratory phase | 7 |
small amount | 7 |
clinical management | 7 |
gut flora | 7 |
three dosing | 7 |
time constant | 7 |
adverse outcomes | 7 |
therapeutic intervention | 7 |
medical treatment | 7 |
ill newborns | 7 |
neonatal mice | 7 |
reach full | 7 |
oris muscle | 7 |
smoke exposure | 7 |
fetal lung | 7 |
protective effects | 7 |
defi nitive | 7 |
may cause | 7 |
pcr testing | 7 |
time points | 7 |
breastfeeding protects | 7 |
campylobacter infections | 7 |
per week | 7 |
transforming growth | 7 |
also contribute | 7 |
small intestinal | 7 |
reason exists | 7 |
associated diarrhea | 7 |
surgical procedures | 7 |
sexual contact | 7 |
deciduous dentition | 7 |
increased incidence | 7 |
infant formulas | 7 |
colonization rates | 7 |
igg preparation | 7 |
close observation | 7 |
incidence rates | 7 |
coagulation necrosis | 7 |
transmitted via | 7 |
weight infant | 7 |
north america | 7 |
maternal serum | 7 |
hav infection | 7 |
children infected | 7 |
throat swabs | 7 |
surrounding structures | 7 |
orally administered | 7 |
nk cells | 7 |
ischemic encephalopathy | 7 |
umbilical venous | 7 |
traumatic brain | 7 |
sepsis syndrome | 7 |
diagnostic tests | 7 |
age range | 7 |
early age | 7 |
caloric intake | 7 |
critical role | 7 |
surgical treatment | 7 |
pneumocystis primary | 7 |
patients survived | 7 |
expression profiling | 7 |
inspiratory time | 7 |
time pcr | 7 |
dysfunctional pattern | 7 |
human disease | 7 |
purulent pericarditis | 7 |
increasing protein | 7 |
therapeutic hypothermia | 7 |
axial length | 7 |
tissue infections | 7 |
may produce | 7 |
neonatal host | 7 |
umbilical vein | 7 |
orbital diameter | 7 |
two months | 7 |
disease due | 7 |
tympanic cavity | 7 |
intestinal epithelium | 7 |
etiologic agent | 7 |
nasal swab | 7 |
sympathetic refl | 7 |
um die | 7 |
clinical disease | 7 |
paediatric patients | 7 |
note springer | 7 |
fecal samples | 7 |
neonatal deaths | 7 |
giardia lamblia | 7 |
throat swab | 7 |
intractable diarrhea | 7 |
significantly reduced | 7 |
may improve | 7 |
open mouth | 7 |
infants fed | 7 |
bacteriostatic effect | 7 |
enteric infections | 7 |
data analysis | 7 |
im vergleich | 7 |
income countries | 7 |
staff members | 7 |
infantile scoliosis | 7 |
neonatal shigellosis | 7 |
frozen plasma | 7 |
decreased risk | 7 |
care personnel | 7 |
macrophage colony | 7 |
preeclampsia group | 7 |
much higher | 6 |
indirect evidence | 6 |
suspected infection | 6 |
auf eine | 6 |
like illness | 6 |
care facilities | 6 |
demographic characteristics | 6 |
nosocomial bloodstream | 6 |
older child | 6 |
nichd neonatal | 6 |
elevated levels | 6 |
constrictor muscles | 6 |
systemic vascular | 6 |
cerebral blood | 6 |
indirect contact | 6 |
disease processes | 6 |
der eltern | 6 |
indigenous australian | 6 |
mrsa infection | 6 |
illness may | 6 |
trial comparing | 6 |
ethmoid bone | 6 |
th day | 6 |
culture positive | 6 |
without treatment | 6 |
growth curves | 6 |
cd ro | 6 |
fatality rate | 6 |
severe lower | 6 |
based precautions | 6 |
medial surface | 6 |
children without | 6 |
artery catheters | 6 |
early postnatal | 6 |
clinical illness | 6 |
high rates | 6 |
fluid intake | 6 |
supplementary material | 6 |
des kindes | 6 |
myeloid differentiation | 6 |
healthy newborns | 6 |
right ventricle | 6 |
higher mortality | 6 |
cystic fi | 6 |
least days | 6 |
mothers whose | 6 |
studies using | 6 |
supportive therapy | 6 |
supplemented formula | 6 |
clinical evolution | 6 |
pediatric emergency | 6 |
group ii | 6 |
less frequent | 6 |
eight patients | 6 |
perinatal care | 6 |
sensory input | 6 |
infections may | 6 |
initial empirical | 6 |
viral loads | 6 |
postnatally acquired | 6 |
mandibular angle | 6 |
craniosacral mechanism | 6 |
infant zidovudine | 6 |
without evidence | 6 |
chest physiotherapy | 6 |
lower incisors | 6 |
fresh frozen | 6 |
risk children | 6 |
may reflect | 6 |
lower rate | 6 |
enrolled infants | 6 |
milk leukocytes | 6 |
breast pump | 6 |
oxidative stress | 6 |
kg per | 6 |
normotensive group | 6 |
survival rates | 6 |
cerebral injury | 6 |
delivery may | 6 |
intravascular catheter | 6 |
care settings | 6 |
infants presenting | 6 |
precautions include | 6 |
long periods | 6 |
immune protection | 6 |
enteritis associated | 6 |
dried blood | 6 |
many infants | 6 |
requiring ventilation | 6 |
functional balance | 6 |
different parts | 6 |
viral lower | 6 |
zeigte sich | 6 |
infants effect | 6 |
global postural | 6 |
low incidence | 6 |
coli isolated | 6 |
pterygoid process | 6 |
tentorium cerebelli | 6 |
susceptibility testing | 6 |
nicu stay | 6 |
function testing | 6 |
index case | 6 |
medications may | 6 |
infected adults | 6 |
group box | 6 |
developmental age | 6 |
preventable diseases | 6 |
lacrimal gland | 6 |
balancing measures | 6 |
decreased significantly | 6 |
shigella dysenteriae | 6 |
extrinsic muscles | 6 |
necrotizing fasciitis | 6 |
pleural fl | 6 |
rrna gene | 6 |
reference values | 6 |
infect dis | 6 |
antibody production | 6 |
infections per | 6 |
improved survival | 6 |
inferior meatus | 6 |
ram cannula | 6 |
contributing factors | 6 |
vital signs | 6 |
lv filling | 6 |
staphylococcal enterotoxin | 6 |
air cells | 6 |
postnatal age | 6 |
results suggest | 6 |
two days | 6 |
reye syndrome | 6 |
tt virus | 6 |
adult respiratory | 6 |
intravenous immunoglobulin | 6 |
respiratory droplets | 6 |
intravenous fl | 6 |
illness caused | 6 |
nursery epidemics | 6 |
orthodontic treatment | 6 |
confl icting | 6 |
optic foramen | 6 |
vitro susceptibility | 6 |
american society | 6 |
frontal process | 6 |
birth weights | 6 |
infant developed | 6 |
oral motor | 6 |
carotid plexus | 6 |
iga antibody | 6 |
one another | 6 |
common symptoms | 6 |
normal lungs | 6 |
may alter | 6 |
perinatal transmission | 6 |
significantly decreased | 6 |
time point | 6 |
tensor tympani | 6 |
less commonly | 6 |
related vibrio | 6 |
fed children | 6 |
plesiomonas shigelloides | 6 |
refi ned | 6 |
blood budesonide | 6 |
required mechanical | 6 |
written informed | 6 |
associated infections | 6 |
hiv status | 6 |
vivianit comp | 6 |
pharmacokinetic differences | 6 |
specific igg | 6 |
respiratory epithelium | 6 |
insertion site | 6 |
invasive devices | 6 |
early recognition | 6 |
inotropic support | 6 |
im verlauf | 6 |
urine output | 6 |
postnatal exposure | 6 |
contact vaccinia | 6 |
eight infants | 6 |
enterocolitis associated | 6 |
igg feeding | 6 |
two parts | 6 |
sphenoidal body | 6 |
beneficial effect | 6 |
infants using | 6 |
pulmo vivianit | 6 |
muscular activity | 6 |
concerning breastfeeding | 6 |
condylar process | 6 |
postnatal day | 6 |
function tests | 6 |
significant association | 6 |
based products | 6 |
normal lung | 6 |
bordetella parapertussis | 6 |
superior rectus | 6 |
salmonella bacteremia | 6 |
particular interest | 6 |
infusion pump | 6 |
infants older | 6 |
spectrum antimicrobial | 6 |
diarrhea may | 6 |
uenza viruses | 6 |
intestinal mucosal | 6 |
pediatric antimicrobial | 6 |
gram negative | 6 |
palatine bones | 6 |
phase iii | 6 |
milk formula | 6 |
placebo controlled | 6 |
bacterial products | 6 |
acute pulmonary | 6 |
virulence plasmid | 6 |
mesenteric lymph | 6 |
intestinal ischemia | 6 |
limited data | 6 |
treatment may | 6 |
parented alimentation | 6 |
und der | 6 |
left ventricular | 6 |
bacterial meningitis | 6 |
und einer | 6 |
promote health | 6 |
aged days | 6 |
intestinal barrier | 6 |
severe nec | 6 |
protein synthesis | 6 |
factors related | 6 |
fatty acid | 6 |
environmental exposures | 6 |
nonimmunosuppressed infants | 6 |
inflammatory bowel | 6 |
highly variable | 6 |
pediatric icus | 6 |
polyunsaturated fatty | 6 |
prospective randomized | 6 |
potential benefits | 6 |
highly sensitive | 6 |
pediatric sepsis | 6 |
endemic areas | 6 |
surveillance system | 6 |
visibly soiled | 6 |
motor development | 6 |
infected newborns | 6 |
trained immunity | 6 |
also occur | 6 |
positive results | 6 |
viral hemorrhagic | 6 |
vascular endothelial | 6 |
postural mechanics | 6 |
second day | 6 |
bronchiolitis obliterans | 6 |
bei neugeborenen | 6 |
infants still | 6 |
enteric nervous | 6 |
commensal organisms | 6 |
diaphragmatic hernia | 6 |
immunization practices | 6 |
cytokine levels | 6 |
human respiratory | 6 |
lower abundance | 6 |
infant population | 6 |
hemodynamically significant | 6 |
feeding behaviors | 6 |
three cases | 6 |
physical exam | 6 |
children enrolled | 6 |
barr virus | 6 |
pediatric population | 6 |
day old | 6 |
case control | 6 |
lower risk | 6 |
age related | 6 |
research ethics | 6 |
cranial dysfunction | 6 |
pediatric practice | 6 |
infants kg | 6 |
complement components | 6 |
masseter muscle | 6 |
lesser wing | 6 |
also known | 6 |
maternal history | 6 |
oral transmission | 6 |
inspired air | 6 |
quantitative variables | 6 |
clinical criteria | 6 |
time course | 6 |
vertebral somatic | 6 |
forms part | 6 |
gastric residuals | 6 |
feeding type | 6 |
host defenses | 6 |
defi ne | 6 |
fulminant course | 6 |
angiogenic factors | 6 |
extracorporeal life | 6 |
arterial pressure | 6 |
field gel | 6 |
enteral alimentation | 6 |
one time | 6 |
high rate | 6 |
antibody titers | 6 |
relative humidity | 6 |
incisor teeth | 6 |
ciliary muscle | 6 |
milk also | 6 |
hyperinfl ation | 6 |
mastoid process | 6 |
nasal septum | 6 |
milk cells | 6 |
hospitalization due | 6 |
nonintact skin | 6 |
pathogenic organisms | 6 |
lrti group | 6 |
care neonatal | 6 |
antigen tests | 6 |
based study | 6 |
anterior displacement | 6 |
care equipment | 6 |
adult volunteers | 6 |
catheter days | 6 |
spontaneous breathing | 6 |
standard deviation | 6 |
virus particles | 6 |
breastfeeding status | 6 |
hudson prongs | 6 |
cardiac failure | 6 |
odds ratios | 6 |
much lower | 6 |
peyer patches | 6 |
iv terbutaline | 6 |
lower border | 6 |
fi xed | 6 |
perinatol doi | 6 |
nasal mask | 6 |
perinatal risk | 6 |
adjusted odds | 6 |
birth trauma | 6 |
blood saturation | 6 |
cystic fibrosis | 6 |
occurs infrequently | 6 |
disease course | 6 |
classifi cation | 6 |
colicky infants | 6 |
heart defects | 6 |
perinatal guidelines | 6 |
increased intra | 6 |
fetal life | 6 |
high levels | 6 |
ow nasal | 6 |
alter von | 6 |
suckling mice | 6 |
care center | 6 |
univariate analysis | 6 |
frenulum linguae | 6 |
ventilator circuit | 6 |
left side | 6 |
lung parenchyma | 6 |
antenatal steroids | 6 |
orofacial structures | 6 |
children older | 6 |
heel prick | 6 |
human intestinal | 6 |
study team | 6 |
activated pmns | 6 |
cervical vertebrae | 6 |
jugular bulb | 6 |
appropriate antimicrobial | 6 |
preterm newborns | 6 |
nucleic acids | 6 |
host cells | 6 |
ed dysfunction | 6 |
wk ga | 6 |
airway narrowing | 6 |
fi fth | 6 |
sich die | 6 |
direct vitamin | 6 |
selective pulmonary | 6 |
past years | 6 |
appropriate state | 6 |
osteopathic manipulation | 6 |
droplet nuclei | 6 |
shoulder dystocia | 6 |
neonatal neutrophils | 6 |
mucosal blood | 6 |
pertussis incidence | 6 |
may take | 6 |
paired structures | 6 |
cigarette smoke | 6 |
child mortality | 6 |
nutritional risk | 6 |
secondary outcomes | 6 |
nasopharyngeal aspirates | 6 |
matrix metalloproteinase | 6 |
tobacco exposure | 6 |
microbial flora | 6 |
pelvic fl | 6 |
orbital surface | 6 |
gbs infection | 6 |
feeding problems | 6 |
perinatal period | 6 |
paediatric emergency | 6 |
current recommendations | 6 |
extracellular traps | 6 |
bowel necrosis | 6 |
chronic mouth | 6 |
rotavirus gastroenteritis | 6 |
observational studies | 6 |
clinical situations | 6 |
feeding mode | 6 |
milk consumption | 6 |
microfl ora | 6 |
hypertrophic pyloric | 6 |
neonatal disease | 6 |
also important | 6 |
der ersten | 6 |
without ph | 6 |
positive sepsis | 6 |
pulmonary edema | 6 |
neuromuscular blockade | 6 |
hgv rna | 6 |
heart surgery | 6 |
rahmen einer | 6 |
infe tion | 6 |
per infant | 6 |
painful defecation | 6 |
young adults | 6 |
genetic factors | 6 |
surface antigen | 6 |
without clinical | 6 |
born kg | 6 |
kg budesonide | 6 |
abdominal distension | 6 |
careful attention | 6 |
epec strains | 6 |
using molecular | 6 |
poliovirus vaccine | 6 |
operating room | 6 |
antimicrobial peptides | 6 |
lung diseases | 6 |
cell death | 6 |
reverse transcription | 6 |
may protect | 6 |
around years | 6 |
effective method | 6 |
vascular supply | 6 |
subplate zone | 6 |
strongly associated | 6 |
single ventricle | 6 |
pertussis vaccination | 6 |
like syndrome | 6 |
children presenting | 6 |
risk newborns | 6 |
continuous variables | 6 |
mild illness | 6 |
plasma levels | 6 |
salmonella meningitis | 6 |
bronchodilator therapy | 6 |
high dose | 6 |
fetal circulation | 6 |
patients may | 6 |
receive intensive | 6 |
daycare centers | 6 |
significantly associated | 6 |
mastoid air | 6 |
atrial block | 6 |
utilizing indirect | 6 |
enterobacter sakazakii | 6 |
i ii | 6 |
international study | 6 |
born prematurely | 6 |
forces applied | 6 |
superior constrictor | 6 |
weeks postmenstrual | 6 |
one child | 6 |
severe pulmonary | 6 |
natural history | 6 |
cytomegalovirus infections | 6 |
healthy individuals | 6 |
pterygoid plate | 6 |
excretion rate | 6 |
siga antibodies | 6 |
least two | 6 |
nvp zdv | 6 |
biological mothers | 6 |
acute gastroenteritis | 6 |
energy metabolism | 6 |
four pregnant | 6 |
plasma concentrations | 6 |
brush border | 6 |
hospital setting | 6 |
united kingdom | 6 |
occipitomastoid suture | 6 |
liver abscess | 6 |
brain damage | 6 |
total number | 6 |
oxygen requirements | 6 |
growth restriction | 5 |
internal ear | 5 |
chronic respiratory | 5 |
faktor xa | 5 |
care setting | 5 |
obstruction due | 5 |
cases occur | 5 |
postoperative period | 5 |
fat globule | 5 |
cases occurred | 5 |
first hour | 5 |
maternal immunization | 5 |
intestinal motility | 5 |
mean value | 5 |
reperfusion injury | 5 |
cellular immune | 5 |
body approach | 5 |
related bloodstream | 5 |
inferior nasal | 5 |
postural pattern | 5 |
financial support | 5 |
will provide | 5 |
infants weighing | 5 |
fragile infants | 5 |
emergency cesarean | 5 |
adhesion molecule | 5 |
cd cd | 5 |
preterm labor | 5 |
systemic inflammation | 5 |
elective cs | 5 |
breastfeeding dyad | 5 |
mycobacterium tuberculosis | 5 |
spectrum antibiotics | 5 |
good outcome | 5 |
viral agents | 5 |
may impact | 5 |
children receiving | 5 |
rotation pattern | 5 |
postnatal corticosteroids | 5 |
nebulized np | 5 |
years later | 5 |
decreased pulmonary | 5 |
breastfeeding may | 5 |
neonates may | 5 |
cord care | 5 |
bacterial cultures | 5 |
first six | 5 |
culture negative | 5 |
secondary outcome | 5 |
nicu patients | 5 |
genital tract | 5 |
nuchal line | 5 |
activator inhibitor | 5 |
received surfactant | 5 |
fetus infection | 5 |
severe infection | 5 |
bacterial diversity | 5 |
mild respiratory | 5 |
patient populations | 5 |
feeding practices | 5 |
cranial bones | 5 |
serum il | 5 |
peripheral arterial | 5 |
randomized trials | 5 |
ill neonates | 5 |
milk feedings | 5 |
anterior wall | 5 |
right upper | 5 |
department visits | 5 |
critical ill | 5 |
staphylococcal scalded | 5 |
formula feeds | 5 |
will affect | 5 |
static compliance | 5 |
prolonged duration | 5 |
integrated eeg | 5 |
virus illness | 5 |
heart rates | 5 |
primary cause | 5 |
cult labor | 5 |
foreign body | 5 |
chennai corresponding | 5 |
isolation precautions | 5 |
pulmonary compliance | 5 |
good results | 5 |
may persist | 5 |
posterior third | 5 |
rate among | 5 |
cardiac cycles | 5 |
occurred within | 5 |
lipid peroxidation | 5 |
review board | 5 |
lateral aspects | 5 |
mesenteric blood | 5 |
ammatory cells | 5 |
electrolyte excretion | 5 |
pathologic findings | 5 |
infrared spectroscopy | 5 |
disordered breathing | 5 |
versus continuous | 5 |
isaac questionnaire | 5 |
complement system | 5 |
dysfunction associated | 5 |
per catheter | 5 |
respiratory bacterial | 5 |
und reifgeborenen | 5 |
chlamydia pneumoniae | 5 |
cord serum | 5 |
der ecmo | 5 |
systemic effects | 5 |
frontal sinus | 5 |
sensitivity testing | 5 |
cgmp anp | 5 |
blood spots | 5 |
posterior pharyngeal | 5 |
tonsillar ring | 5 |
another report | 5 |
somatic growth | 5 |
asthma control | 5 |
potential role | 5 |
see appendix | 5 |
surveillance data | 5 |
drain placement | 5 |
except one | 5 |
newborn intensive | 5 |
eff ects | 5 |
osteopathic manipulative | 5 |
density lipoprotein | 5 |
bone growth | 5 |
dependent diabetes | 5 |
typically associated | 5 |
important aspect | 5 |
etiologic diagnosis | 5 |
infant care | 5 |
medial rectus | 5 |
vs vs | 5 |
upper lip | 5 |
und reifgeborene | 5 |
small bowel | 5 |
feeding infants | 5 |
insuffi cient | 5 |
may indicate | 5 |
campylobacter species | 5 |
antimicrobial susceptibility | 5 |
mucosal level | 5 |
available concerning | 5 |
way anova | 5 |
neonatal group | 5 |
pharyngeal airway | 5 |
postnatal weeks | 5 |
mean time | 5 |
continuous flow | 5 |
significant effect | 5 |
also seems | 5 |
secretory response | 5 |
weight group | 5 |
will continue | 5 |
cairo university | 5 |
dysfunctional patterns | 5 |
born preterm | 5 |
patients infected | 5 |
holder pasteurization | 5 |
pn days | 5 |
hospitalization rates | 5 |
multicentre study | 5 |
prolonged breastfeeding | 5 |
ventricular septal | 5 |
dust mite | 5 |
lateral rotation | 5 |
und ohne | 5 |
epidemiologic investigation | 5 |
sga infants | 5 |
therapeutic approach | 5 |
including infants | 5 |
south african | 5 |
pulmonary vasodilator | 5 |
study shows | 5 |
ecmo program | 5 |
vitreous body | 5 |
major risk | 5 |
industrialized countries | 5 |
severe diarrhea | 5 |
multiple regression | 5 |
neutralizing antibody | 5 |
lateral strain | 5 |
infant crying | 5 |
muscles originate | 5 |
discriminatory power | 5 |
within postnatal | 5 |
wurde ein | 5 |
survival without | 5 |
intubated elgans | 5 |
endemic area | 5 |
nontyphoidal salmonella | 5 |
lung maturation | 5 |
improve clinical | 5 |
infants via | 5 |
whole body | 5 |
accepted definitions | 5 |
higher education | 5 |
fluid secretion | 5 |
kg hr | 5 |
computed tomography | 5 |
latin america | 5 |
gene probe | 5 |
gastric emptying | 5 |